Analyst Price Target is $19.50
▲ +155.91% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for WAVE Life Sciences in the last 3 months. The average price target is $19.50, with a high forecast of $26.00 and a low forecast of $12.00. The average price target represents a 155.91% upside from the last price of $7.62.
Current Consensus is
Moderate Buy
The current consensus among 11 contributing investment analysts is to moderate buy stock in WAVE Life Sciences. This rating has held steady since June 2025, when it changed from a Buy consensus rating.
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Read More
